Table 1 VRE Sample Demographics (n = 533)
VRE Status | |||
|---|---|---|---|
Variable | VRE Positive (n = 65) | VRE Negative, Gram Negative (n = 80) | VRE Negative, Sterile (n = 306) |
Age | 53.4 (11.1)a | 56.2 (10.6) | 55.5 (9.7) |
Sex | |||
Male | 24 (36.9%) | 43 (53.7%) | 205 (67.0%) |
Female | 41 (63.1%) | 37 (46.3%) | 101 (33.0%) |
Raceb | |||
White | 17 (26.1%) | 22 (27.5%) | 117 (38.2%) |
African-American | 1 (1.5%) | 5 (6.3%) | 6 (2.0%) |
Hispanic | 41 (63.1%) | 47 (58.7%) | 145 (47.4%) |
Asian | 4 (6.2%) | 4 (5.0%) | 23 (7.5%) |
Other | 2 (3.1%) | 2 (2.5%) | 15 (4.9%) |
Child Pugh Scoreb | |||
A | 1 (1.5%) | 9 (11.2%) | 27 (8.8%) |
B | 14 (21.5%) | 28 (35.0%) | 127 (41.5%) |
C | 50 (76.9%) | 43 (53.8%) | 152 (49.7%) |
MELD Scoreb | 25.4 (9.9) | 20.3 (8.8) | 19.7 (9.7) |
Culture Siteb | |||
Blood | 12 (18.5%) | 20 (43.5%) | 62 (49.6%) |
Urine | 43 (66.1%) | 20 (43.5%) | 47 (37.6%) |
Ascitic fluid | 4 (6.2%) | 4 (8.7%) | 14 (11.2%) |
Pleural fluid | 0 | 0 | 0 |
BAL | 5 (7.7%) | 2 (4.3%) | 1 (0.8%) |
Wound | 1 (1.5%) | 0 | 1 (0.8%) |
Transplant Historyb | |||
None | 48 (73.8%) | 62 (77.5%) | 238 (78.6%) |
Liver | 13 (20.0%) | 13 (16.3%) | 57 (18.8%) |
Liver/kidney | 4 (6.2%) | 5 (6.2%) | 8 (2.6%) |
VRE Treatmentb | |||
No treatment | 12 (19.1%) | ||
Linezolid | 36 (57.1%) | ||
Daptomycin | 11 (17.5%) | ||
Tigecycline | 4 (6.3%) | ||